Detecting Plasma Tumor DNA in Early-Stage Breast Cancer—Letter

Beaver and colleagues ([1][1]) reported that the detection of mutant PIK3CA circulating tumor DNA (ctDNA) in early-stage breast cancer patients before and after surgery could improve selection of systemic postsurgical therapies. They reported that 14 of 15 patients with PIK3CA mutations in the